Table 2.

Circulating the VEGF-A Level According to Different Features of Patients With HCC.

Patients characteristic	Groups of variable	The mean circulating VEGF-A level (range)	P value
Age	≤ 60	241.6 (26.3-1414.1)	0.6
	>60	272.5 (45.7-1367.1)
Gender	Female	277.5 (39.1-277.1)	0.8
	Male	258.5 (26.3-1414.1)
Cirrhosis status	No	322.5 (28.5-1414.1)	0.03*
	Yes	193.9 (26.3-772.1)
The largest tumor size	≤ 5 cm	132.7 (26.3-345.9)	<0.001*
	>5 cm	342.1 (28.5-1414.1)
Number of Tumor lesions	Uninodularity	260.7 (28.5-1414.1)	0.9
	Multinodularity	265.1 (26.3-1367.1)
Lymph node involvement	No	258.1 (28.5-1414.1)	0.8
	Yes	270.2 (30.4-849.2)
Portal vein involvement	No	212.3 (26.3-1367.1)	0.06
	Yes	332.1 (28.5-1414.1)
Serum AFP level	≤ 400	174.8 (26.3-1367.1)	0.001*
	>400	407.2 (76.3-1414.1)
Serum ALT value	≤ 40	225.8 (26.3-1072.9)	0.1
	>40	318.4 (28.5-1414.1)
Serum AST level	≤45	179.6 (28.9-1072.9)	0.012*
	>45	324.4 (26.3-1414.1)
Serum Bilirubin	≤ 2	243.5 (28.5-1367.1)	0.2
	>2	362.4 (26.3-1414.1)
Hepatitis infection (HBV or HCV)	Negative	342.9 (26.3-1414.1)	0.006*
	Positive	174.5 (28.5-843.1)
Albumin	≤3.5	307.6 (28.9-1367.1)	0.3
	>3.5	241.1 (26.3-1414.1)
INR	≤1.2	262.9 (28.5-1367.1)	0.9
	>1.2	255.9 (26.3-1414.1)
The BCLC stage	Very early	132.9 (132.9 -132.9)	0.02*
	Early	148.8 (55.5-286.3)
	Intermediate	149.3 (26.3-498.9)
	Advanced	318.2 (28.5-1414.1)
	Terminal	650.2 (457.4-843.1)
The first-line treatment	Surgery	181.6 (60.6-286.3)	0.3
	Systemic cytotoxic treatment	331.3 (28.5-1414.1)
	Tyrosine kinase	379.7 (30.4-1367.1)
	RFA or MVA	123.8 (79.1-170.3)
	TACE or TARE	211.5 (26.3-772.1)
	BSC	382.5 (86.9-843.1)
	Not reported	212.1 (55.5-480.2)
Child-Turcotte-Pugh class	A	242.5 (28.5-1367.1)	0.07
	B	270.6 (26.3-1414.1)
	C	618.8 (457.4-843.1)